BR9815367A - Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile - Google Patents

Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile

Info

Publication number
BR9815367A
BR9815367A BR9815367-6A BR9815367A BR9815367A BR 9815367 A BR9815367 A BR 9815367A BR 9815367 A BR9815367 A BR 9815367A BR 9815367 A BR9815367 A BR 9815367A
Authority
BR
Brazil
Prior art keywords
prophylaxis
therapy
diseases
toxin
clostridium difficile
Prior art date
Application number
BR9815367-6A
Other languages
English (en)
Inventor
Christoph Von Eichel-Streiber
Michael Moos
Original Assignee
Christoph Von Eichel Streiber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Von Eichel Streiber filed Critical Christoph Von Eichel Streiber
Publication of BR9815367A publication Critical patent/BR9815367A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SEQuêNCIAS DE AMINOáCIDOS PARA TERAPIA E PROFILAXIA DE DOENçAS ATRAVéS DA TOXINA CLOSTRIDIUM DIFFICILE". A invenção se refere aos anticorpos monoclonais, capazes de reconhecer e neutralizar os epítopos dos domínios da ligadura , dos domínios de translocação ou dos domínios catalíticos da enterotoxina (toxina A) e da citotoxina (toxina B) da Clostridium difficile, assim como sua produção e sua aplicação na terapia e profilaxia de doenças da toxina mencionada.
BR9815367-6A 1997-09-10 1998-09-10 Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile BR9815367A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
PCT/EP1998/005759 WO1999012971A2 (de) 1997-09-10 1998-09-10 Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine

Publications (1)

Publication Number Publication Date
BR9815367A true BR9815367A (pt) 2001-11-06

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815367-6A BR9815367A (pt) 1997-09-10 1998-09-10 Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile

Country Status (11)

Country Link
US (2) US6667035B1 (pt)
EP (1) EP0994904B1 (pt)
JP (1) JP4318398B2 (pt)
CN (1) CN1273588A (pt)
AT (1) ATE254139T1 (pt)
AU (1) AU9742698A (pt)
BR (1) BR9815367A (pt)
CA (1) CA2303202C (pt)
DE (2) DE19739685A1 (pt)
ES (1) ES2210832T3 (pt)
WO (1) WO1999012971A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1358331A2 (en) * 2001-02-09 2003-11-05 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
EP1609491B1 (en) * 2004-06-16 2008-02-06 Straumann Holding AG Barrier membrane
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
NZ595386A (en) 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
EP2459588B1 (de) * 2009-07-27 2016-06-29 BioDics GmbH Verfahren zum nachweis und zur identifikation eines varianten c. difficile stammes in einer probe
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
EP4365196A3 (en) 2011-04-22 2024-08-07 Wyeth LLC Compositions relating to a mutant clostridium difficile toxin and methods thereof
SG10201804809RA (en) * 2011-08-22 2018-07-30 Cnj Holdings Inc Clostridium difficile antibodies
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
TWI592422B (zh) * 2012-03-02 2017-07-21 再生元醫藥公司 抗艱難梭狀芽孢桿菌毒素之人類抗體
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105025926B (zh) * 2012-11-28 2018-12-14 Cnj控股公司 针对艰难梭菌的抗体
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
EP0153519B1 (en) 1984-03-02 1988-06-01 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Also Published As

Publication number Publication date
CA2303202A1 (en) 1999-03-18
WO1999012971A2 (de) 1999-03-18
DE19739685A1 (de) 1999-03-11
US20040137601A1 (en) 2004-07-15
CN1273588A (zh) 2000-11-15
WO1999012971A3 (de) 1999-07-22
ATE254139T1 (de) 2003-11-15
EP0994904A2 (de) 2000-04-26
US7151159B2 (en) 2006-12-19
US6667035B1 (en) 2003-12-23
CA2303202C (en) 2010-04-27
AU9742698A (en) 1999-03-29
ES2210832T3 (es) 2004-07-01
JP4318398B2 (ja) 2009-08-19
EP0994904B1 (de) 2003-11-12
JP2001515920A (ja) 2001-09-25
DE59810172D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
BR9815367A (pt) Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile
Arroyo et al. Molecular basis of host epithelial cell recognition by Trichomonas vaginalis
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
RU2571212C2 (ru) Средства и способы получения высокоочищенного нейротоксина
PT624377E (pt) Conjugados de farmacos antitumorais clivaveis por enzimas lisossomicas
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
HRP20080430A2 (en) HUMANIZED ANTIBODIES THAT SEQUESTER αC PEPTIDE
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
PT807125E (pt) Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase
YU49370B (sh) Postupak za pripremanje vakcine protiv lajmske bolesti
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
RS50926B (sr) Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
Tanjoni et al. Snake venom metalloproteinases: structure/function relationships studies using monoclonal antibodies
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
Halpern et al. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
Ehrlich et al. Monoclonal antibodies to. alpha.-chain regions of human fibrinogen that participate in polymer formation
DK1165615T3 (da) Monoklonale antistoffer mod humant protein Mcm3, proces til deres fremstilling af deres anvendelse
ES2139568T3 (es) Complejo proteico.
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
Harshman et al. Staphylococcal α-toxin: a structure-function study using a monoclonal antibody
Simpson et al. Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIO